Seeking Alpha

Novartis (NVS): Q1 net profit -16.6% to $2.31B vs. consensus of $2.16B; revenue stagnated as new...

Novartis (NVS): Q1 net profit -16.6% to $2.31B vs. consensus of $2.16B; revenue stagnated as new products were unable to fully compensate for weaker sales of blockbuster Diovan. CEO Joe Jimenez warns Diovan will take an even bigger hit in Q3 when its U.S. patent expires. Shares -1.1% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|